Q2 2026 13F · SEC CIK 1855655
Paradigm Biocapital Advisors LP
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $5.3B
- Reported positions
- 28
- Top holdings a year, 3 yrs
- +31.9%
- Assets under management
- $4.5B
Paradigm Biocapital Advisors LP is a hedge fund that reported 28 positions worth $5.3B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Revolution Medicines Inc (RVMD, 22.3%), Nuvalent Inc (NUVL, 13.7%), Edgewise Therapeutics Inc (EWTX, 7.8%). A portfolio copying its top holdings returned 31.9% a year over the last 3 years, against 20.4% for the S&P 500.
Paradigm Biocapital Advisors LP holdings all 28 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Paradigm Biocapital Advisors LP bought and sold in Q2 2026, against Q1 2026.
New positions
- ALNY Alnylam Pharmaceuticals Inc2.7% of 13F
- MBX Mbx Biosciences Inc2.6% of 13F
- Jade Biosciences Inc1.2% of 13F
- ACHV Achieve Life Science Inc0.6% of 13F
- MPLT Maplight Therapeutics Inc0.5% of 13F
- KARD Kardigan Inc0.4% of 13F
- EDIT Editas Medicine Inc0.3% of 13F
Added to
- ASMB Assembly Biosciences Inc.+133.6% shares
- VRDN Viridian Therapeutics Inc+113.5% shares
- SYRE Spyre Therapeutics+96.2% shares
- GMAB Genmab A/s+64.8% shares
- TNGX Tango Therapeutics Inc+58.6% shares
- EWTX Edgewise Therapeutics Inc+38.7% shares
- APGE Apogee Therapeutics Inc+16.9% shares
- NUVL Nuvalent Inc+11.3% shares
Reduced
- PCVX Vaxcyte Inc-55.6% shares
- LXEO Lexeo Therapeutics Inc-32.5% shares
- TYRA Tyra Biosciences Inc-11.0% shares
- ERAS Erasca, Inc.-8.1% shares
- EYPT Eyepoint Pharmaceuticals Inc-8.0% shares
- ORKA Oruka Therapeutics Inc-7.6% shares
Sold out
- ACLX Arcellx Incwas 13.5%
- CNTA Centessa Pharmaceuticals PLCwas 2.9%
- TERN Terns Pharmaceuticals Incwas 2.4%
- CYTK Cytokineticswas 2.0%
- ABVX Abivax SAwas 1.8%
- MAZE Maze Therapeutics Incwas 1.7%
- SRRK Scholar Rock Hldg Corpwas 1.2%
- MIRM Mirum Pharmaceuticals Incwas 1.2%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +104.0% /yr
- S&P 500 +20.1%
- 3 years
- +31.9% /yr
- S&P 500 +20.4%
- 5 years
- +21.8% /yr
- S&P 500 +13.0%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $5.3B | 28 |
| Q1 2026 | $4.9B | 35 |
| Q4 2025 | $3.7B | 29 |
| Q3 2025 | $3.4B | 33 |
| Q2 2025 | $2.3B | 28 |
| Q1 2025 | $2.2B | 27 |
| Q4 2024 | $2.9B | 28 |
| Q3 2024 | $2.9B | 31 |
| Q2 2024 | $2.6B | 35 |
| Q1 2024 | $2.8B | 34 |
| Q4 2023 | $2.1B | 29 |
| Q3 2023 | $1.5B | 29 |
Questions about Paradigm Biocapital Advisors LP's portfolio
What stocks does Paradigm Biocapital Advisors LP own?
Paradigm Biocapital Advisors LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 28 positions worth $5.3B. The largest are Revolution Medicines Inc (RVMD) at 22.3%, Nuvalent Inc (NUVL) at 13.7%, Edgewise Therapeutics Inc (EWTX) at 7.8%, Genmab A/s (GMAB) at 6.8% and Spyre Therapeutics (SYRE) at 6.4%.
What did Paradigm Biocapital Advisors LP buy last quarter?
In Q2 2026, Paradigm Biocapital Advisors LP added a new position in Alnylam Pharmaceuticals Inc (ALNY), a new position in Mbx Biosciences Inc (MBX), a new position in Jade Biosciences Inc, a new position in Achieve Life Science Inc (ACHV), a new position in Maplight Therapeutics Inc (MPLT), Assembly Biosciences Inc. (ASMB) (+133.6% shares), Viridian Therapeutics Inc (VRDN) (+113.5% shares) and Spyre Therapeutics (SYRE) (+96.2% shares), compared with its Q1 2026 filing.
What did Paradigm Biocapital Advisors LP sell last quarter?
In Q2 2026, Paradigm Biocapital Advisors LP sold all of Arcellx Inc (ACLX), sold all of Centessa Pharmaceuticals PLC (CNTA), sold all of Terns Pharmaceuticals Inc (TERN), sold all of Cytokinetics (CYTK), sold all of Abivax SA (ABVX), Vaxcyte Inc (PCVX) (-55.6% shares), Lexeo Therapeutics Inc (LXEO) (-32.5% shares) and Tyra Biosciences Inc (TYRA) (-11.0% shares), compared with its Q1 2026 filing.
How has Paradigm Biocapital Advisors LP's portfolio performed?
A portfolio copying Paradigm Biocapital Advisors LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +31.9% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +104.0% against +20.1%. Over 5 years: +21.8% a year against +13.0%.
When is Paradigm Biocapital Advisors LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Paradigm Biocapital Advisors LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Paradigm Biocapital Advisors LP manage?
Paradigm Biocapital Advisors LP reported $4.5B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $5.3B.